Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 801 to 850 of 2052 results for work

  1. Ixekizumab for treating moderate to severe plaque psoriasis (TA442)

    Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults.

  2. Using our recommendations: cardiovascular disease

    How to use NICE guidance to reduce health inequalities in people experiencing cardiovascular disease (CVD).

  3. Using our recommendations: maternity and neonatal health

    How to use NICE guidance to reduce health inequalities during and after pregnancy.

  4. Stage 4: treatment, assessment and monitoring

    In virtual wards, people can receive virtual and technology-assisted treatment, assessment, and monitoring.

  5. Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn's disease and ulcerative colitis (ES35)

    Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis

  6. Supporting people to plan for the future: What is the effectiveness and cost-effectiveness of early, preventative support for people with complex needs?

    needs. Source guidance details Comes from guidance Social work with adults experiencing complex needs Number NG216 Date

  7. Organisational-level approaches for all organisations: What is the long-term impact and cost effectiveness of employee assistance programme provision on mental wellbeing?

    Source guidance details Comes from guidance Mental wellbeing at work Number NG212 Date issued March 2022 Other details

  8. 3C Patch for treating diabetic foot ulcers (HTG615)

    Evidence-based recommendations on 3C Patch for treating diabetic foot ulcers.

  9. Erenumab for preventing migraine (TA682)

    Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.

  10. Helping people to connect with local communities and reduce isolation: What social and community support approaches are effective in promoting social inclusion of people with complex needs?

    communities. Source guidance details Comes from guidance Social work with adults experiencing complex needs Number NG216 Date

  11. Pneumonia: diagnosis and management (NG250)

    This guideline covers diagnosing, assessing, and treating community-acquired and hospital-acquired pneumonia, including bacterial pneumonia secondary to COVID-19, in babies over 1 month (corrected gestational age), children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.

  12. Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)

    Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.

  13. QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)

    NICE has developed a medtech innovation briefing (MIB) on QuickChange Incontinence Wrap for urinary incontinence in men .

  14. Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)

    Evidence-based recommendations on fostamatinib (Tavlesse) for chronic refractory chronic immune thrombocytopenia in adults.

  15. Percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain (HTG399)

    Evidence-based recommendations on percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain. This involves relieving low back pain by delivering heat energy to the damaged disc.

  16. What interventions are effective and cost effective at raising awareness of the health risks of damp and mould in the home?

    risk for those who cannot afford remedial work or have to rely on landlords or property managers to do the work. In both...

  17. Tacrolimus and pimecrolimus for atopic eczema (TA82)

    Evidence-based recommendations on tacrolimus (Protopic) and pimecrolimus (Elidel) for people with atopic eczema.

  18. Ozanimod for treating relapsing–remitting multiple sclerosis (TA706)

    Evidence-based recommendations on ozanimod (Zeposia) for treating relapsing–remitting multiple sclerosis in adults with clinical or imaging features of active disease.

  19. Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)

    Evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in adults.

  20. Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis (TA1096)

    Evidence-based recommendations on benralizumab (Fasenra) for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis in adults.

  21. Secondary prevention after a myocardial infarction (QS99)

    This quality standard covers preventing further cardiovascular disease after a myocardial infarction (heart attack). It includes assessment and cardiac rehabilitation. It describes high-quality care in priority areas for improvement.

  22. Cystic fibrosis (QS168)

    This quality standard covers diagnosing and managing cystic fibrosis in infants, children, young people and adults. It describes high-quality care in priority areas for improvement.

  23. Emergency and acute medical care in over 16s (QS174)

    This quality standard covers the organisation and delivery of emergency and acute medical care in the community and in hospital. It covers adults (16 and over) who seek, or are referred for, emergency NHS care for a suspected or confirmed acute medical emergency. It describes high-quality care in priority areas for improvement.

  24. Polysomnography:- Does treating obstructive sleep apnoea perioperatively improve outcomes?

    postoperative outcomes. However, it is frequently undiagnosed before surgery. Work is ongoing to examine whether obstructive sleep...

  25. Polysomnography:- Does preoperative screening of people who are at risk of obstructive sleep apnoea with polysomnography identify those at higher risk of postoperative complications?

    postoperative outcomes. However, it is frequently undiagnosed before surgery. Work is ongoing to examine whether obstructive sleep...

  26. Cystic fibrosis: diagnosis and management (NG78)

    This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.

  27. Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31)

    This guideline covers recognising, assessing, diagnosing and treating obsessive-compulsive disorder and body dysmorphic disorder in adults, young people and children (aged 8 years and older). It aims to improve the diagnosis and treatment of obsessive-compulsive disorder and body dysmorphic disorder. It includes recommendations on how families and carers may be able to support people with either of these conditions, and how they can get support for themselves.

  28. Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA1077)

    Evidence-based recommendations on nemolizumab (Nemluvio) for treating moderate to severe atopic dermatitis in people 12 years and over.

  29. Fremanezumab for preventing migraine (TA764)

    Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.

  30. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for uterine prolapse

    Normal arrangement of organs in a woman's pelvis 3 Which type of surgery works best, and which has the most complications? There's...

  31. Online help programme recommended for people with eating disorders

    An online therapy programme can be used to help people aged 16 and over with eating disorders whilst they wait for specialist NHS treatment, an independent NICE has said.

  32. Care pathway:- In the UK, what is the optimal care pathway for young people and adults with coexisting severe mental illness and substance misuse?

    and staff within each service often lack the knowledge and skills needed to work effectively with people from another organisation.A...

  33. What is the most clinically and cost-effective tinnitus questionnaire to assess tinnitus in people who are d/Deaf or who have a severe-to-profound hearing loss?

    contain questions related to the effect of tinnitus on communication, social or work activities or distress from communication problems...

  34. Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (TA988)

    Evidence-based recommendations on ivacaftor–tezacaftor–elexacaftor (Kaftrio) plus ivacaftor (Kalydeco), tezacaftor–ivacaftor (Symkevi) plus ivacaftor, and lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis.

  35. Faltering growth: recognition and management of faltering growth in children (NG75)

    This guideline covers recognition, assessment and monitoring of faltering growth in infants and children. It includes a definition of growth thresholds for concern and identifying the risk factors for, and possible causes of, faltering growth. It also covers interventions, when to refer, service design, and information and support.

  36. Pancreatitis (NG104)

    This guideline covers managing acute and chronic pancreatitis in children, young people and adults. It aims to improve quality of life by ensuring that people have the right treatment and follow-up, and get timely information and support after diagnosis.

  37. Communication:- What are the most clinically effective and cost-effective methods of addressing patient and carer concerns about strong opioids, including anticipating and managing adverse effects, and engaging patients in prescribing decisions?

    notes(if applicable) Why this is important:- We know from qualitative work that patients do not always understand how to take strong...

  38. Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) (HTG401)

    Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease.

  39. Joint replacement (primary): hip, knee and shoulder (NG157)

    This guideline covers care before, during and after a planned knee, hip or shoulder replacement. It includes recommendations to ensure that people are given full information about their options for surgery, including anaesthesia. It offers advice for healthcare professionals on surgical procedures and ensuring safety during operations. It also offers guidance on providing support and rehabilitation before and after surgery.

  40. Multiple pregnancy: twin and triplet pregnancies (QS46)

    This quality standard covers the additional antenatal care for women who are pregnant with twins or triplets that is offered alongside routine antenatal care. It describes high-quality care in priority areas for improvement.

  41. How cost effective are fluoride varnish programmes and tooth-brushing schemes?

    out, and the effect on independent living such as admissions to care homes, work related effects including sickness absence. Source...

  42. How can healthy habits that promote oral health be supported and encouraged in families with children at high risk of poor oral health?

    out, and the effect on independent living such as admissions to care homes, work related effects including sickness absence. Source...

  43. Intravenous fluid therapy in adults in hospital (QS66)

    This quality standard covers managing intravenous (IV) fluid therapy safely and effectively for adults in hospital. It describes high-quality care in priority areas for improvement.

  44. Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over (TA1002)

    Evidence-based recommendations on evinacumab (Evkeeza) for treating homozygous familial hypercholesterolaemia in people 12 years and over.

  45. Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)

    Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in adults.

  46. Spinal metastases and metastatic spinal cord compression (NG234)

    This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neurological injury and improve prognosis.

  47. Adults' uptake of and engagement with interventions for social anxiety disorder:- What methods are effective in improving uptake of and engagement with interventions for adults with social anxiety disorder?

    years or more for it. This question should be addressed by a programme of work that tests a number of strategies to improve uptake and...

  48. What are the barriers that women experience to achieving blood glucose targets?

    barriers in this cohort of women is needed so that healthcare professionals can work to overcome them. Robust qualitative studies are...

  49. Fenfluramine for treating seizures associated with Dravet syndrome (TA808)

    Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Dravet syndrome in people aged 2 and older.